0R15 9025.0 0.0% 0R1E 9410.0 0.0% 0M69 None None% 0R2V 247.99 9682.643% 0QYR 1567.5 0.0% 0QYP 439.3701 -2.9016% 0RUK None None% 0RYA 1597.0 1.2682% 0RIH 195.55 0.0% 0RIH 191.4 -2.1222% 0R1O 225.5 9683.0803% 0R1O None None% 0QFP 10475.8496 107.8542% 0M2Z 252.573 0.2373% 0VSO 33.0 -7.3164% 0R1I None None% 0QZI 622.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 222.05 -4.1318%
Last update at 2024-12-19T18:55:00Z
BDX Stock Up on Robotics Solution Launch to Boost Single-Cell Research
Tue 15 Oct 24, 04:22 PMIs Becton, Dickinson and Company (NYSE:BDX) Worth US$237 Based On Its Intrinsic Value?
Mon 14 Oct 24, 02:00 PMWhy Becton Dickinson (BDX) is a Top Value Stock for the Long-Term
Mon 14 Oct 24, 01:40 PMWill Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
Fri 11 Oct 24, 04:10 PMHere's Why Becton Dickinson (BDX) is a Strong Momentum Stock
Mon 07 Oct 24, 01:50 PMBecton Dickinson in pact to to resolve vast majority of hernia litigation
Thu 03 Oct 24, 09:05 PMThree Reasons Why You Should Hold BDX Stock in Your Portfolio Now
Thu 03 Oct 24, 04:09 PM| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | 1662.00M | 1783.00M | 2242.00M | 985.00M | 1163.00M |
| Minority interest | - | - | - | - | - |
| Net income | 1484.00M | 1779.00M | 2092.00M | 874.00M | 1220.00M |
| Selling general administrative | 4719.00M | 4709.00M | 1.00M | -7.00000M | 2.00M |
| Selling and marketing expenses | - | - | 4867.00M | 4325.00M | 4332.00M |
| Gross profit | 8170.00M | 8477.00M | 9427.00M | 7577.00M | 8288.00M |
| Reconciled depreciation | 2288.00M | 2229.00M | 2273.00M | 2154.00M | 2253.00M |
| Ebit | 2427.00M | 2282.00M | 2799.00M | 1484.00M | 1760.00M |
| Ebitda | 4715.00M | 4602.00M | 5169.00M | 3976.00M | 4535.00M |
| Depreciation and amortization | 2288.00M | 2320.00M | 2370.00M | 2492.00M | 2775.00M |
| Non operating income net other | - | -101.00000M | -88.00000M | 30.00M | - |
| Operating income | 2111.00M | 2282.00M | 2799.00M | 1484.00M | 1760.00M |
| Other operating expenses | 16948.00M | 16395.00M | 17265.00M | 15324.00M | 15050.00M |
| Interest expense | 452.00M | 398.00M | 469.00M | 528.00M | 639.00M |
| Tax provision | 132.00M | 148.00M | 150.00M | 111.00M | -7.00000M |
| Interest income | 49.00M | 16.00M | 460.00M | 501.00M | 626.00M |
| Net interest income | -403.00000M | -382.00000M | -460.00000M | -521.00000M | -627.00000M |
| Extraordinary items | -46.00000M | 144.00M | 488.00M | 522.00M | 50.00M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 132.00M | 148.00M | 150.00M | 111.00M | -57.00000M |
| Total revenue | 19372.00M | 18870.00M | 20248.00M | 17117.00M | 17290.00M |
| Total operating expenses | 5746.00M | 6002.00M | 6444.00M | 5784.00M | 6048.00M |
| Cost of revenue | 11202.00M | 10393.00M | 10821.00M | 9540.00M | 9002.00M |
| Total other income expense net | -359.00000M | -499.00000M | -557.00000M | -499.00000M | -597.00000M |
| Discontinued operations | - | 144.00M | 144.00M | 144.00M | 144.00M |
| Net income from continuing ops | 1530.00M | 1635.00M | 2092.00M | 874.00M | 1233.00M |
| Net income applicable to common shares | 1424.00M | 1689.00M | 2002.00M | 767.00M | 1081.00M |
| Preferred stock and other adjustments | - | 90.00M | 90.00M | 107.00M | - |
| Breakdown | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
| Total assets | 57286.00M | 52780.00M | 52934.00M | 53866.00M | 54012.00M |
| Intangible assets | 10917.00M | 552.00M | 12311.00M | 12784.00M | 13813.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1291.00M | 1380.00M | 1712.00M | 1071.00M | 891.00M |
| Total liab | 31397.00M | 26984.00M | 27633.00M | 30189.00M | 30237.00M |
| Total stockholder equity | 25911.00M | 25796.00M | 25301.00M | 23677.00M | 23775.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 4722.00M | 5500.00M | 3933.00M | 6126.00M | 5116.00M |
| Common stock | 371.00M | 371.00M | 365.00M | 365.00M | 365.00M |
| Capital stock | - | - | 367.00M | 367.00M | 367.00M |
| Retained earnings | 16139.00M | 15535.00M | 15157.00M | 13826.00M | 12791.00M |
| Other liab | - | - | 5936.00M | 6453.00M | 6851.00M |
| Good will | 26465.00M | 24522.00M | 24621.00M | 23901.00M | 23620.00M |
| Other assets | - | 2078.00M | 1.00M | -1.00000M | 1269.00M |
| Cash | 1856.00M | 1416.00M | 1006.00M | 2283.00M | 2825.00M |
| Cash and equivalents | - | 1416.00M | 1006.00M | 2283.00M | 2825.00M |
| Total current liabilities | 8956.00M | 6641.00M | 7811.00M | 6626.00M | 5823.00M |
| Current deferred revenue | - | -1641.00000M | - | -1793.00000M | -1355.00000M |
| Net debt | 18254.00M | 14463.00M | 15059.00M | 15327.00M | 15106.00M |
| Short term debt | 2170.00M | 1141.00M | 2179.00M | 500.00M | 707.00M |
| Short long term debt | - | 1141.00M | 2179.00M | 500.00M | 707.00M |
| Short long term debt total | 20110.00M | 15879.00M | 16065.00M | 17610.00M | 17931.00M |
| Other stockholder equity | 9401.00M | 11438.00M | 11265.00M | 11572.00M | 13165.00M |
| Property plant equipment | - | 6557.00M | 6012.00M | 6393.00M | 5923.00M |
| Total current assets | 10468.00M | 8676.00M | 8141.00M | 8838.00M | 8969.00M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | -11631.00000M | -13007.00000M | -13671.00000M |
| Short term investments | 445.00M | 8.00M | 8.00M | 12.00M | 20.00M |
| Net receivables | 3033.00M | 2534.00M | 2191.00M | 2497.00M | 2398.00M |
| Long term debt | - | 14738.00M | 13886.00M | 17110.00M | 17224.00M |
| Inventory | 3843.00M | 3273.00M | 3224.00M | 2866.00M | 2743.00M |
| Accounts payable | 1896.00M | 1641.00M | 1699.00M | 1793.00M | 1355.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | -1548.00000M | -1488.00000M | -2088.00000M | -2548.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 365.00M | 365.00M | 365.00M |
| Preferred stock total equity | - | - | 2.00M | 2.00M | 2.00M |
| Retained earnings total equity | - | - | 15157.00M | 13826.00M | 12791.00M |
| Treasury stock | - | - | -8330.00000M | -7723.00000M | -6138.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2615.00M | 2078.00M | -3361.00000M | 1952.00M | 1687.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 46818.00M | 44104.00M | 44792.00M | 45029.00M | 45043.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | 14738.00M | 13886.00M | 17110.00M | 17224.00M |
| Breakdown | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
| Investments | - | -716.00000M | -3231.00000M | -1880.00000M | -1232.00000M |
| Change to liabilities | - | -517.00000M | -473.00000M | 687.00M | 205.00M |
| Total cashflows from investing activities | - | -716.00000M | -3220.00000M | -1880.00000M | -1232.00000M |
| Net borrowings | - | -723.00000M | -78.00000M | -243.00000M | -1760.00000M |
| Total cash from financing activities | 2087.00M | -1957.00000M | -591.00000M | -3306.00000M | 22.00M |
| Change to operating activities | - | 192.00M | -1394.00000M | 282.00M | 81.00M |
| Net income | 1705.00M | 1530.00M | 1779.00M | 2092.00M | 874.00M |
| Change in cash | 375.00M | 322.00M | -1233.00000M | -525.00000M | 2327.00M |
| Begin period cash flow | 1481.00M | 1159.00M | 2392.00M | 2917.00M | 590.00M |
| End period cash flow | 1856.00M | 1481.00M | 1159.00M | 2392.00M | 2917.00M |
| Total cash from operating activities | 3844.00M | 2989.00M | 2633.00M | 4647.00M | 3539.00M |
| Issuance of capital stock | - | - | 0.00000M | 0.00000M | 2917.00M |
| Depreciation | 2286.00M | 2288.00M | 2229.00M | 2273.00M | 2154.00M |
| Other cashflows from investing activities | - | 158.00M | -177.00000M | -141.00000M | -421.00000M |
| Dividends paid | 1100.00M | 1114.00M | 1082.00M | 1048.00M | 1026.00M |
| Change to inventory | 98.00M | -15.00000M | -631.00000M | -104.00000M | -125.00000M |
| Change to account receivables | - | -290.00000M | 32.00M | -95.00000M | -48.00000M |
| Sale purchase of stock | -500.00000M | 0.00000M | -500.00000M | -1750.00000M | 3389.00M |
| Other cashflows from financing activities | -88.00000M | 1312.00M | 1796.00M | -265.00000M | -109.00000M |
| Change to netincome | - | -153.00000M | 155.00M | -20.00000M | 372.00M |
| Capital expenditures | 725.00M | 874.00M | 973.00M | 1231.00M | 810.00M |
| Change receivables | - | - | 32.00M | -95.00000M | -48.00000M |
| Cash flows other operating | - | - | 1180.00M | -515.00000M | 108.00M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | -1485.00000M | -539.00000M | 2329.00M |
| Change in working capital | - | -828.00000M | -1394.00000M | 282.00M | 512.00M |
| Stock based compensation | 247.00M | 259.00M | 233.00M | 237.00M | 244.00M |
| Other non cash items | -183.00000M | 362.00M | -94.00000M | 67.00M | 57.00M |
| Free cash flow | 3119.00M | 2115.00M | 1660.00M | 3416.00M | 2729.00M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BDX Becton Dickinson and Company |
1.06 0.47% | 225.15 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
| ISRG Intuitive Surgical Inc |
3.11 0.59% | 529.58 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
-0.64 0.53% | 119.68 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
-3.5 1.44% | 240.00 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| ALC Alcon AG |
0.01 0.01% | 84.75 | 36.95 | 25.13 | 4.40 | 2.32 | 4.80 | 36.97 |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880
| Name | Title | Year Born |
|---|---|---|
| Mr. Thomas E. Polen Jr. | Pres, CEO & Chairman | 1973 |
| Mr. Christopher DelOrefice | Exec. VP & CFO | 1971 |
| Mr. Samrat S. Khichi Esq. | Exec. VP of Corp. Devel., Public Policy & Regulatory Affairs and Gen. Counsel | 1967 |
| Mr. Thomas J. Spoerel | Sr. VP, Controller & Chief Accounting Officer | 1978 |
| Ms. Elizabeth McCombs | Exec. VP & Chief Technology Officer | 1976 |
| Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. | Sr. VP, Chief Scientific Officer & Co-Chair of Scientific Advisory Board | NA |
| Ms. Denise Fleming | Exec. VP of Technology & Global Services and Chief Information Officer | NA |
| Ms. Francesca M. DeMartino | Sr. VP & Head of Investor Relations | NA |
| Michelle Quinn | Sr. VP and Chief Ethics & Compliance Officer | NA |
| Troy Kirkpatrick | VP of PR | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...